A new term for Dr. Mona Nemer; U of T’s response to monkeypox outbreak paves the way for collaborations with Canadian and international groups, a rebound in Canadian angel investment stats, and more.
Topic: health sciences
The Short Report, May 6, 2020: AbCellera receives $175.6M for COVID-19 therapies; Canada contributes $850 million to global pandemic response; new “super angel” fund launches; and more
Vancouver-based AbCellera Biologics will receive up to $175.6 million from the federal Strategic Innovation Fund to fast-track antibody therapies against COVID-19. The funding will also go to build a first-of-its-kind antibody manufacturing facility over the next four years to help Canada respond to future pandemics. AbCellera has partnered with global biopharmaceutical company Eli Lilly to…
The Short Report, April 1, 2020: EU will integrate COVID-19 stimulus with green transition; researchers team up to share resources and materials in fight against COVID-19; and more
The European Union will adapt its economic response to the COVID-19 pandemic in support of the continent-wide Green Deal adopted in December. Europe wants to eliminate greenhouse gas emissions by 2050 through a growth strategy that will “transform its economy and society to put it on a more sustainable path.” In a new statement, EU’s leaders…
The Short Report, March 25, 2020: Tech CEOs implore Ottawa to protect their industry, the NGEN supercluster commits $50M to scaling up production of supplies to fight COVID-19, and more
The Canadian Institutes of Health Research launched a new COVID-19 funding opportunity for operating grants called the “COVID-19 Clinical Epidemiology Research Rapid Response.” The application deadline is this Friday, March 27, and successful applicants will be notified of the decision on April 1. The competition description emphasizes the viruses “many unknown epidemiological parameters, particularly with respect…
Accel-RX co-founder Natalie Dakers comes full circle with adMare BioInnovations
Now joined with Admare BioInnovations, the Vancouver-based business accelerator Accel-Rx will be able to offer better opportunities to grow for early-stage health sciences companies.